Advanced Accelerator Applications : Announces Pricing of Initial Public Offering

170dcb9f-6795-4a47-86c5-fbc218459b54.pdf

PRESS RELEASE

Advanced Accelerator Applications S.A. Announces Pricing of Initial Public Offering

10 November 2015, Saint-Genis-Pouilly, France - Advanced Accelerator Applications S.A. ('AAA' or the 'Company'), an international specialist in Molecular Nuclear Medicine (MNM), today announced the pricing of its initial public offering of 4,688,000 American Depositary Shares ('ADSs') representing 9,376,000 of its ordinary shares at a price of $16.00 per ADS. The ADSs are expected to begin trading on the Nasdaq Global Select Market on November 11, 2015 under the ticker 'AAAP.' All of the ADSs are being offered by AAA. In addition, AAA has granted the underwriters a 30-day option to purchase up to 703,200 additional ADSs from the Company at the initial public offering price, less underwriting discounts.

Citigroup Global Markets Inc. and Jefferies LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. and JMP Securities LLC are acting as co-managers.

A registration statement relating to these securities has been filed with, and declared effective by, the Securities and Exchange Commission.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer of ADSs in any Member State of the European Economic Area which has implemented the Prospectus Directive (each, a 'Relevant Member State') will be made pursuant to an exemption under the Prospectus Directive, as implemented in that Relevant Member State, from the requirement to publish a prospectus for offers of securities.

The offering will be made only by means of a prospectus, copies of which may be obtained, when available, from Citigroup Global Markets Inc. by calling toll-free [phone] or from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022 or by calling [phone] or by emailing [e-mail].

About Advanced Accelerator Applications

Advanced Accelerator Applications (AAA) is a radiopharmaceutical company founded in 2002 to develop innovative molecular nuclear medicine products. AAA's main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions ('Personalized Medicine').

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain forward-looking statements. All statements, other than statements of historical facts, contained in this press release, including statements regarding the Company's strategy, future operations, future financial position, future revenues, projected costs, prospects, plans

and objectives of management, are forward-looking statements. The words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'predict,' 'project,' 'target,' 'potential,' 'will,' 'would,' 'could,' 'should,' 'continue,' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward- looking statements reflect the Company's current expectation regarding future events. These forward- looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, EMA, U.S. FDA and other regulatory approvals for our product candidates, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

AAA Media Relations

Laetitia Defaye Véronique Mermet

Head of Corporate Communications Communications Officer

[e-mail] [e-mail]

Tel: [phone] Tel: [phone]

AAA Investor Relations

Jordan Silverstein

Director of Investor Relations [e-mail] Tel: + 1-212-235-2394

Media enquiries

FTI Consulting

Kimberly Ha [e-mail] Tel: [phone]

iCorporate (Italy)

Elisa Piacentino [e-mail]

Tel: [phone]